Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW), a late-stage biotechnology company dedicated to the treatment of medical and aesthetic skin diseases and conditions, is excited to announce its presentation at the upcoming Life Sciences Investor Forum. The forum will be hosted by VirtualInvestorConferences.com on Thursday, November 14, 2024, at 12:00 PM ET. Gerry Proehl, the Company’s Chairman, President, and Chief Executive Officer will lead the presentation.
Event Details:
- Date: November 14, 2024
- Time: 12:00 PM – 12:30 PM ET
This live, interactive online event invites both individual and institutional investors to engage with Dermata Therapeutics. Participants will have the opportunity to ask real-time questions. For those unable to attend, an archived webcast will be available following the event. Dermata encourages online investors to pre-register to expedite their participation and receive timely event updates.
Recent Dermata Highlights
Dermata continues to make significant strides in their research and development efforts. Recent achievements include:
- Impressive efficacy, safety, and tolerability results from a Phase 2b clinical trial in treating moderate to severe acne.
- Progressing towards the completion of enrollment in their DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, with top-line results anticipated in the first quarter of 2025.
- A large, addressable market exists, with an estimated 30 million patients in the US alone seeking effective acne treatments.
- Active discussions with potential botulinum toxin partners to advance the development of DMT410 for topical delivery of botulinum toxin.
- Successful fundraising efforts have resulted in $7.8 million in gross proceeds from financial activities completed in 2024.
About Dermata Therapeutics
Based in San Diego, California, Dermata Therapeutics is at the forefront of biotechnology in skin disease treatment. The Company’s lead product candidate, DMT310, originates from a pioneering Spongilla technology platform. This once-weekly topical treatment, derived from a naturally sourced freshwater sponge, exhibits multiple unique mechanisms of action and has been investigated for use in acne, rosacea, and psoriasis treatment. DMT410, their second product candidate, leverages Spongilla technology for a novel method of topical intradermal delivery of botulinum toxin, aimed at treating hyperhidrosis and various aesthetic skin conditions.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) stands as a premier investor conference series, seamlessly connecting publicly traded companies with investors through an interactive forum. This innovative platform replicates the dynamics of on-site investor conferences by enhancing company presentations with dynamic video content and facilitating efficient one-on-one investor meetings. VIC serves as an essential tool for companies aiming to reach a global network of retail and institutional investors.
Forward-Looking Statements
All forward-looking statements made during this press release are based on the current beliefs and expectations of Dermata Therapeutics. These statements, by their nature, involve risks and uncertainties. Actual outcomes may differ significantly from these statements due to new or evolving risks, clinical trial results, and other unforeseen factors. Dermata underscores the importance of understanding these risks as they proceed with their ambitious plans for product development and regulatory submissions.
This brief has been provided to engage and update interested parties about Dermata Therapeutics’ forthcoming presentation and ongoing developments in the vibrant field of dermatological biotechnology. The team remains committed to advancing their groundbreaking therapies to address the needs of patients with skin diseases and conditions.
